Bottom line
Is RXL a good fund? The bottom line
RXL is an actively managed health care sector ETF from ProShares.
Its expense ratio is 0.95% — about $95 a year on every $10,000 invested, cheaper than 50% of health care sector funds we track.
It returned +19.7% over one year, +7.2% a year over five years, +12.6% a year over ten (as of Dec 31, 2025, per its prospectus).
With $72.1 million in net assets and 70 holdings, its largest position is Eli Lilly & Co. (12.7%) and the top 10 make up 57.8% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 78% top-holdings overlap).
What stands out
- 5-year return beat 88% of category peers
What to watch
- Concentrated: top 10 holdings are 57.8% of assets
Updated Nov 19, 2026
What RXL invests in
ProShares Ultra Health Care (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the S&P Health Care Select Sector Index (the Index).
The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of health care companies included in the S&P 500 Index. The S&P 500 Index is designed to measure the performance of 500 of the largest companies listed and domiciled in the U.S. The Index includes health care companies in the following industries according to the Global Industry Classification Standard (GICS): health care equipment & supplies, health care providers & services; health care technology; biotechnology; pharmaceuticals; and life sciences tools & services. These companies are then weighted based on market capitalization. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March, June, and December. The Index is…
From the fund's prospectus (filed Sep 25, 2026).
RXL performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RXL | +19.7% | +7.2% | +12.6% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What RXL costs
On a $10,000 investment, RXL's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,305 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
RXL top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co. | 12.67% |
| 2 | ProShares GENIUS Money Market ETF | 11.81% |
| 3 | Johnson & Johnson | 7.86% |
| 4 | AbbVie, Inc. | 5.57% |
| 5 | UnitedHealth Group, Inc. | 4.98% |
| 6 | Merck & Co., Inc. | 4.26% |
| 7 | Repurchase Agreement | 2.91% |
| 8 | Thermo Fisher Scientific, Inc. | 2.68% |
| 9 | Amgen, Inc. | 2.62% |
| 10 | Gilead Sciences, Inc. | 2.41% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 57.8% of the fund. See all top 25 holdings and asset mix →
Alternatives to RXL
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 78% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 78% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 76% | Compare |
| iShares | IXJ iShares Global Healthcare ETF | 0.38% | 73% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 51% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 68% | Compare |